<DOC>
	<DOCNO>NCT00688883</DOCNO>
	<brief_summary>To assess antitumor effect safety Fludara patient indolent lymphoma .</brief_summary>
	<brief_title>Fludara ( Oral ) Phase II Study Indolent Lymphoma</brief_title>
	<detailed_description>As 29 May 2009 , clinical trial sponsor Genzyme Corporation . NOTE : This study originally post sponsor Schering AG , Germany , subsequently rename Bayer Schering Pharma AG , Germany .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>Patients histologically cytologically confirm indolent lymphoma ( include mantle cell lymphoma ) Patients measurable lesion ( major axis &gt; 1.5 cm CT ) Patients fail PR previous chemotherapy antibody therapy . Patients subsequent relapse previously attain CR subsequent recurrence previously attain PR Patients receive chemotherapy , antibody therapy radiotherapies 4 week ( 3 month case antibody therapy ) Patients PS Grade 0 2 criterion ECOG Patients adequately maintain organ function Patients infectious disease , serious complication , serious gastrointestinal symptom , serious bleeding tendency ( DIC ) , CNS metastases , fever 38 degree Celsius , interstitial pneumonia pulmonary fibrosis , active malignancy , AIHA history allergy similar purine analog Patients positive HBs antigen , HCV antibody HIV antibody Patients receive GCSF blood transfusion within 1 week screen test Patients ever receive previous therapy fludarabine phosphate injection ( Fludara ) , pentostatin ( Coforin ) , cladribine ( Leustatin ) SH T 586 Patients pregnant , childbearing potential , lactating , agree practice contraception</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>74 Years</maximum_age>
	<verification_date>December 2013</verification_date>
	<keyword>Fludarabine</keyword>
	<keyword>Purine analog</keyword>
	<keyword>Indolent lymphoma</keyword>
</DOC>